These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23831603)

  • 1. HIV-1 Vpu - an ion channel in search of a job.
    Strebel K
    Biochim Biophys Acta; 2014 Apr; 1838(4):1074-81. PubMed ID: 23831603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of viral protein U (Vpu) with cellular factors.
    Guatelli JC
    Curr Top Microbiol Immunol; 2009; 339():27-45. PubMed ID: 20012522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms.
    Andrew A; Strebel K
    Mol Aspects Med; 2010 Oct; 31(5):407-17. PubMed ID: 20858517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
    Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
    Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of HIV-1 Vpu protein for virus spread and pathogenesis.
    Nomaguchi M; Fujita M; Adachi A
    Microbes Infect; 2008 Jul; 10(9):960-7. PubMed ID: 18672082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
    Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
    Miyagi E; Andrew AJ; Kao S; Strebel K
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2868-73. PubMed ID: 19196977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of biological activity with computationally derived structural features from transmembrane hetero-dimers of HIV-1 Vpu with host factors.
    Li LH; Fischer WB
    Biochim Biophys Acta; 2014 Apr; 1838(4):1104-12. PubMed ID: 24036078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
    Andrew AJ; Miyagi E; Kao S; Strebel K
    Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
    PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
    Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
    mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
    Dubé M; Bego MG; Paquay C; Cohen ÉA
    Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
    Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
    J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.